Published in World J Hepatol on June 18, 2015
Relationship between TRAF6 and deterioration of HCC: an immunohistochemical and in vitro study. Cancer Cell Int (2016) 0.77
Optimizing the Detection of Circulating Markers to Aid in Early Lung Cancer Detection. Cancers (Basel) (2016) 0.76
Detection of Autoantibodies to Vascular Endothelial Growth Factor Receptor-3 in Bile Duct Ligated Rats and Correlations with a Panel of Traditional Markers of Liver Diseases. Dis Markers (2016) 0.75
Hepatocellular carcinoma. Lancet (2003) 22.54
Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study. Lancet Oncol (2012) 4.21
Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol (2006) 2.97
Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol (2009) 2.41
A novel cytoplasmic protein with RNA-binding motifs is an autoantigen in human hepatocellular carcinoma. J Exp Med (1999) 2.36
Enhancement of antibody detection in cancer using panel of recombinant tumor-associated antigens. Cancer Epidemiol Biomarkers Prev (2003) 2.14
Antibody detection using tumor-associated antigen mini-array in immunodiagnosing human hepatocellular carcinoma. J Hepatol (2006) 2.11
Cloning and characterization of a novel 90 kDa 'companion' auto-antigen of p62 overexpressed in cancer. Oncogene (2002) 1.95
Serum autoantibodies as biomarkers for early cancer detection. FEBS J (2009) 1.94
A systematic review of humoral immune responses against tumor antigens. Cancer Immunol Immunother (2009) 1.75
Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest (1993) 1.66
Elevated serum antibodies against insulin-like growth factor-binding protein-2 allow detecting early-stage cancers: evidences from glioma and colorectal carcinoma studies. Ann Oncol (2012) 1.49
Cancer immunomics using autoantibody signatures for biomarker discovery. Mol Cell Proteomics (2007) 1.47
A new type of protein chip to detect hepatocellular carcinoma-related autoimmune antibodies in the sera of hepatitis C virus-positive patients. Proteome Sci (2013) 1.44
Hepatocellualar carcinoma serum markers. Semin Oncol (2012) 1.39
Tumor markers for hepatocellular carcinoma. Mol Clin Oncol (2013) 1.35
Tumor-associated antigen arrays for the serological diagnosis of cancer. Mol Cell Proteomics (2006) 1.32
Autoantibodies to tumor-associated antigens as diagnostic biomarkers in hepatocellular carcinoma and other solid tumors. Expert Rev Mol Diagn (2010) 1.23
A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics (2002) 1.22
Autoantibodies to tumor-associated antigens combined with abnormal alpha-fetoprotein enhance immunodiagnosis of hepatocellular carcinoma. Cancer Lett (2009) 1.16
Humoral immune response to p16, a cyclin-dependent kinase inhibitor in human malignancies. Oncol Rep (2006) 1.15
De-novo humoral immune responses to cancer-associated autoantigens during transition from chronic liver disease to hepatocellular carcinoma. Clin Exp Immunol (2001) 1.15
Using proteomic approach to identify tumor-associated antigens as markers in hepatocellular carcinoma. J Proteome Res (2008) 1.13
Immune response to cyclin B1 in hepatocellular carcinoma. Hepatology (1997) 1.09
New serum markers of hepatocellular carcinoma. Semin Oncol (2012) 1.09
Significance of autoantibodies against insulin-like growth factor II mRNA-binding proteins in patients with hepatocellular carcinoma. Int J Oncol (2005) 1.08
Analyses of autoantibodies against tumor-associated antigens in patients with hepatocellular carcinoma. Int J Oncol (2005) 1.02
Harnessing immunity for cancer marker discovery. Nat Biotechnol (2003) 0.99
Proteomic analysis of autoantibodies in patients with hepatocellular carcinoma. Proteomics (2006) 0.98
The diversity expression of p62 in digestive system cancers. Clin Immunol (2005) 0.98
Diagnosis of hepatocellular carcinoma: newer radiological tools. Semin Oncol (2012) 0.98
Identification of hepatocellular-carcinoma-associated antigens and autoantibodies by serological proteome analysis combined with protein microarray. J Proteome Res (2008) 0.95
Autoantibodies against glucose-regulated protein 78 as serological diagnostic biomarkers in hepatocellular carcinoma. Int J Oncol (2012) 0.89
Identification of tumor-associated antigens by using SEREX in hepatocellular carcinoma. Cancer Lett (2009) 0.88
Screening of autoantibodies as potential biomarkers for hepatocellular carcinoma by using T7 phase display system. Cancer Epidemiol (2011) 0.87
Identification of HCC-22-5 tumor-associated antigen and antibody response in patients. Clin Chim Acta (2005) 0.86
Autoantibodies to tumor-associated antigens as biomarkers in human hepatocellular carcinoma (HCC). Exp Hematol Oncol (2013) 0.85
Clinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancer. World J Gastroenterol (2013) 0.84
Use of autoantibodies to detect the onset of breast cancer. J Immunol Res (2014) 0.84
Autoantibody recognition of an N-terminal epitope of hnRNP L marks the risk for developing HBV-related hepatocellular carcinoma. J Proteomics (2013) 0.84
Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma. J Clin Pathol (1996) 0.83
Autoantibodies to survivin in patients with chronic hepatitis and hepatocellular carcinoma. Autoimmunity (2005) 0.83
Evaluation of the pattern and prognostic implications of anti-p53 in hepatocellular carcinoma. Singapore Med J (2007) 0.83
Calreticulin is a B cell molecular target in some gastrointestinal malignancies. Clin Exp Immunol (2009) 0.83
Serum anti-Ku86 is a potential biomarker for early detection of hepatitis C virus-related hepatocellular carcinoma. Biochem Biophys Res Commun (2012) 0.83
Serum autoantibody measurement for the detection of hepatocellular carcinoma. PLoS One (2014) 0.83
Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma. Hepatogastroenterology (2009) 0.82
Clinical evaluation of autoantibodies to p53 protein in patients with chronic liver disease and hepatocellular carcinoma. Eur J Cancer (1998) 0.81
Chaperonopathies and chaperonotherapy. Hsp60 as therapeutic target in cancer: potential benefits and risks. Curr Pharm Des (2013) 0.80
Immunogenicity of Ra1A and its tissue-specific expression in hepatocellular carcinoma. Int J Immunopathol Pharmacol (2009) 0.80
Identification of tumor-associated antigens in human hepatocellular carcinoma by autoantibodies. Oncol Rep (2008) 0.80